Lymphoma Clinical Trials

Showing 1801-1820 of 2,926 trials

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

NCT04264039

The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, based on open clinical trials, using patients' T cells might encounter the failure of apheresis available T cells, even if successful, the time needed for the manufacture could also cause the irreversible disease progress. Furthermore, the cost of auto-CAR-T cells is not affordable for most patients. So to provide an accessible and affordable anti-CD19 CAR-T cell therapy for patients with B-cell hematologic malignancies, we launch such a trial that using the edited T cells from healthy donors to manufacture universal CAR-T cells and adapt it in patients with CD19+ B-cell leukemia or lymphoma.

B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma

Xinqiao Hospital of Chongqing30 participantsStarted Apr 2020

Chongqing, Chongqing Municipality, China

UNKNOWN

Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM

NCT02364050

Prospective data collection of a consecutive series of elderly patients with large B-cell lymphoma newly diagnosed, receiving before the start of treatment Multidimensional Geriatric Assessment (VGM) through the use of Activity of Daily Living (ADL), Instrumental Activity of Daily Living (IADL) and Cumulative Illness Rating Scale for Geriatrics (CIRS-G).

Lymphoma, Large B-Cell, Diffuse

Fondazione Italiana Linfomi - ETS1,300 participantsStarted Sep 2013

Treviglio, Bergamo, Italy • Tricase, LE, Italy • Rozzano, Milano, Italy +52 more locations

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM

Related Searches

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT